High expression of CCNB1 driven by ncRNAs is associated with a poor prognosis and tumor immune infiltration in breast cancer

Abstract

Backgrounds: Breast cancer (BC) is the most frequent cancer diagnosed in women throughout the world. The purpose of this study was to explore new biomarkers for breast cancer diagnosis. CyclinB1 (CCNB1) is found in abundance in a wide range of human malignancies. Material and Methods: We evaluated the transcriptional, survival data and expression levels in tissue data of CCNB1 in patients with breast cancer from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), The Human Protein Atlas (THAP) and Genome Tissue Expression (GTEx) database. A series of in silico analyses were used to investigate at noncoding RNAs (ncRNAs), gene ontology (GO) annotation analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG), and the Protein-Protein Interaction (PPI) network. A quantitative real-time polymerase chain reaction (qRT-PCR) was used to validate CCNB1 in BC cell lines. Results: CCNB1 expression was higher in BC tissues than in normal breast tissues. It was significantly related to survival time, tumor mutation burden (TMB), methylated, immune cell infiltration, and the expressed in estrogen receptor (ER) (−), lymphnode (+), and p53 (+) groups in BC. Moreover, The AC026401.3/CCNB1-miR-139-5p axis was discovered as the most promising upstream ncRNA-related pathway of CCNB1 in BC. Conclusion: CCNB1 can be used as an independent predictive factor for BC, indicating that this would be a target for highly precise therapy and a biomarker for the disease.

Identification and functional analysis of lactic acid metabolism-related differentially expressed genes in hepatocellular carcinoma

“…Targeting the E2F1/SEC61G pathway increased response to chemotherapy in hypopharyngeal squamous cell carcinoma through immune response ( Li et al, 2022 ). High CCNB1expression is associated with tumor immune infiltration and poor prognosis in breast cancer ( Fu et al, 2022 ). Combining NQO1 inhibitors with conventional chemotherapeutics might enhance anti-tumor immune effects in non-small cell lung cancer ( Madajewski et al, 2023 ).…”

Identification of Hub Genes for Psoriasis and Cancer by Bioinformatic Analysis

“…DLGAP is a kinetochore fiber-binding protein that functions as an oncoprotein in many cancers. Overexpression of CCNB1, CCNB2, DLGAP5, and ASPM is associated with tumor progression and poor prognosis [ 23 – 27 ]. NCAPG is a chromosome condensation protein associated with mitosis and meiosis, responsible for the condensation and stability of chromosomes during these processes.…”

A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma

“…These lncRNAs are known to play important roles in a variety of cancers. For example, AC026401.3 acts on OCT1 to enhance drug resistance to sorafenib in hepatocellular carcinoma ( 49 ), and AC026401.3 regulates breast cancer progression by regulating CCNB1 ( 50 ). EMX2OS plays an important role in the prognosis of gastric cancer ( 51 ) and regulates proliferation and invasion of ovarian cancer through the miR-654-3p/AKT3/PD-L1 regulatory axis ( 52 ).…”

“…These lncRNAs are known to play important roles in a variety of cancers. For example, AC026401.3 acts on OCT1 to enhance drug resistance to sorafenib in hepatocellular carcinoma (49), and AC026401.3 regulates breast cancer progression by regulating CCNB1 (50).…”